Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (15963)	8/13/2002 9:17:12 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

You know that your beloved FDA does not demand any particular trial. DNA/Xoma had to run additional trials to get the number of subjects treated with Genetech produced Raptiva up to the agreed upon level. DNA apparently believed that a "weaning" trial offered the best bang for the buck, since no matter how logical it is that a condition comes back when a treatment is halted, even some doctors as well as many message board posters do not understand this, or at least pretend not to.